Make systematic detail document to follow to take daily ICU round in oncology ICU and evaluate the patient
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
"oncology" AND "intensive care unit" AND "rounds" AND "patient evaluation"
Searching the Web
oncology ICU daily rounds checklist systematic evaluation 2024
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading Web Page
ICU daily rounds checklist patient evaluation oncology
Finding Sources
Finding Sources
Searching PubMed
"cancer" AND "intensive care" AND "outcomes"
Searching the Web
oncology ICU specific complications assessment chemotherapy toxicity ventilation 2024 guidelines
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Running Command
The document is valid (proper ZIP/DOCX structure, 28KB). Here is your complete guide:
Oncology ICU Daily Rounds Guide
Word Document · DOCX
What's Inside the Document
The guide is structured into 10 sections with color-coded tables, checkboxes, and oncology-specific action thresholds:
Section 1 - Patient Snapshot
A summary table capturing malignancy type/stage, current regimen, cycle day, reason for admission, and code status - to orient the entire rounding team in 30 seconds.
Section 2 - Overnight Events & 24-Hour Summary
Checkbox table for overnight clinical events, interventions performed, medication changes, lab alerts acted on, and family communication.
Section 3 - Vital Signs & Monitoring Trends
Tabular review of all vital parameters with oncology-specific targets (e.g., fever threshold in neutropenic patients, urine output target for TLS).
Section 4 - System-by-System Review (9 subsystems)
| Subsystem | Key Oncology Overlays |
|---|---|
| 4A Respiratory | ICI pneumonitis grading, bleomycin FiO2 precaution, PCP treatment, leukostasis |
| 4B Cardiovascular | Anthracycline cardiomyopathy, QTc monitoring for targeted agents, ICI myocarditis |
| 4C Neurology | PRES (cisplatin/bevacizumab), CNS metastases, ifosfamide encephalopathy (methylene blue) |
| 4D Renal / Fluids | Full TLS protocol (Cairo-Bishop criteria, rasburicase, dialysis indications), cisplatin nephrotoxicity |
| 4E GI / Nutrition | Mucositis grading, VOD/SOS in SCT (defibrotide), CINV antiemetics, TPN indications |
| 4F Hematology | ANC thresholds, DIC assessment, G-CSF use, HIT screening, transfusion triggers |
| 4G Infection | Febrile neutropenia < 60 min antibiotic rule, MASCC risk scoring, antifungal escalation, HAI bundles |
| 4H Oncology-Specific | Chemotherapy toxicity review, metabolic emergencies (hypercalcemia, SIADH, spinal cord compression, SVC, leukostasis), CRS/ICANS grading for CAR-T, GVHD |
| 4I-J Lines, Skin & Mobility | CAUTI/CLABSI prevention, pressure injury (Braden), early mobility (ICU scale) |
Section 5 - Daily Lab Review
Nine lab groups with oncology action thresholds - including TLS panel (uric acid, LDH, phosphate, ionized Ca), ferritin for HLH/CRS, drug level monitoring (vancomycin AUC, MTX levels, calcineurin inhibitor troughs).
Section 6 - Medication Reconciliation
Renal/hepatic dose adjustments, drug-drug interactions (azoles + TKIs), irradiated/CMV-negative blood products for immunocompromised patients, antiemetic adequacy.
Section 7 - Goals of Care
Code status, family meeting documentation, chemotherapy continuation risk-benefit, palliative care integration, ethics consultation trigger points.
Section 8 - Daily Problem List & Orders
Structured problem-plan format with space for labs, imaging, procedures, consults, and next-day targets.
Section 9 - ABCDEF Bundle + Oncology Add-Ons
Liberation bundle (A-Pain, B-SAT/SBT, C-Sedation choice, D-Delirium, E-Mobility, F-Family) plus neutropenic isolation compliance, CRS monitoring for CAR-T, GVHD surveillance, chemotherapy safe handling.
Section 10 - SBAR Handoff Template
Structured handoff covering situation, background, assessment, recommendation, anticipated deterioration triggers, upcoming procedures, and family contact plan.
This is a shared conversation. Sign in to Orris to start your own chat.